Our purpose

Supporting life-changing therapies through long-term strategic partnerships

Our investment thesis

We are a Life Sciences venture fund backing private biotech companies in Europe and North America, with special focus in Spain and Portugal.
We team up with driven entrepreneurs and fellow investors who aim to revolutionize healthcare through disruptive and well-protected innovations that have the potential to transform patients’ lives where there is a significant unmet medical need.
We invest agnostically across modalities and disease areas, offering evergreen support until achieving meaningful impact.

Founders spotligh

Disruptive companies improving patients’ lives

Our manifesto

Our founders’ insights and achievements

Criteria Bio Ventures leads €27 Mn round in AbolerIS Pharma to advance therapies against autoimmune diseases

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of €205M


Decades of experience backing innovation

”la Caixa” Foundation

Years of commitment with society and healthcare

We have a strong legacy to the values of ”la Caixa” Foundation, one of the largest foundations of the world, with 100+ years of history and a commitment with society and healthcare.


Billions of euros under management

We are the evergreen Life Sciences venture capital arm of CriteriaCaixa, the holding that manages the wealth of ”la Caixa” Foundation.

Caixa Capital Risc

Years of VC experience 

Criteria Bio Ventures is the new specialized vehicle of Caixa Capital Risc (the venture capital arm of CriteriaCaixa) fully dedicated to investments in the Life Sciences. As such, we stand on 15+ years of venture capital experience of CCR, one of the first VC funds in Spain to invest in this sector.


Spin-offs since 2015

Alongside our investment activity, we have launched the CaixaImpulse programme, to facilitate tech transfer and develop companies in their early stages. The programme, currently managed by ”la Caixa” Foundation with our support, has provided funding to over 200 projects conducted by research institutions in Spain and Portugal. Notably, 40 of these projects have successfully given rise to spin-offs.